Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 17934 | 512 | 26.6 | 75% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 2067 | 4822 | DCE MRI//CT PERFUSION//INTRAVOXEL INCOHERENT MOTION |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | RECIST | Author keyword | 34 | 37% | 15% | 75 |
| 2 | RECIST 11 | Author keyword | 7 | 56% | 2% | 9 |
| 3 | TUMOR MEASUREMENT | Author keyword | 7 | 57% | 2% | 8 |
| 4 | TARGET LESION | Author keyword | 5 | 54% | 1% | 7 |
| 5 | RECIST RESPONSE EVALUATION CRITERIA IN SOLID TUMORS | Author keyword | 4 | 75% | 1% | 3 |
| 6 | TUMOR MEASUREMENTS | Author keyword | 3 | 57% | 1% | 4 |
| 7 | MODIFIED RECIST 11 | Author keyword | 3 | 100% | 1% | 3 |
| 8 | TUMOR RESPONSE | Author keyword | 3 | 11% | 5% | 27 |
| 9 | TUMOR RESPONSE ASSESSMENT | Author keyword | 3 | 40% | 1% | 6 |
| 10 | RESPONSE EVALUATION CRITERIA IN SOLID TUMORS RECIST | Author keyword | 3 | 45% | 1% | 5 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | RECIST | 23 | 30% | 12% | 63 |
| 2 | US CANCER CENTERS | 21 | 90% | 2% | 9 |
| 3 | GUIDELINE VERSION 11 | 12 | 49% | 4% | 18 |
| 4 | AUTOMATED CT VOLUMETRY | 11 | 78% | 1% | 7 |
| 5 | RESPONSE EVALUATION CRITERIA | 7 | 26% | 5% | 25 |
| 6 | RECIST CRITERIA | 7 | 36% | 3% | 16 |
| 7 | INTRAOBSERVER VARIABILITY | 7 | 23% | 5% | 26 |
| 8 | RECIST GUIDELINE | 6 | 50% | 2% | 8 |
| 9 | TARGET LESIONS | 5 | 63% | 1% | 5 |
| 10 | LUNG NODULE VOLUMETRY | 4 | 75% | 1% | 3 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| RECIST revisited: A review of validation studies on tumour assessment | 2006 | 254 | 39 | 46% |
| Measures of response: RECIST, WHO, and new alternatives | 2006 | 140 | 36 | 50% |
| RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline | 2010 | 46 | 57 | 37% |
| Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence | 2010 | 26 | 29 | 38% |
| Quantifying the probability of clinical trial success from scientific articles | 2014 | 0 | 1 | 100% |
| RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox Point | 2012 | 10 | 26 | 31% |
| State of the Art: Assessment in Lung Cancer in the Era of Genomic Medicine | 2014 | 7 | 104 | 13% |
| The Use of Volumetric CT as an Imaging Biomarker in Lung Cancer | 2010 | 15 | 21 | 33% |
| Pitfalls in RECIST Data Extraction for Clinical Trials: Beyond the Basics | 2015 | 0 | 15 | 60% |
| Tumor Response Evaluation in Oncology: Current Update | 2010 | 16 | 31 | 26% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | US IMAGING INTERVENT UII | 1 | 100% | 0.4% | 2 |
| 2 | PHARSIGHT CONSULTING SERV | 1 | 33% | 0.6% | 3 |
| 3 | BIOSYST SYNTHET GENOM NETWORK MED | 1 | 50% | 0.2% | 1 |
| 4 | CANC CELL INVAS | 1 | 50% | 0.2% | 1 |
| 5 | DANA FARBER CANC IMAGING | 1 | 50% | 0.2% | 1 |
| 6 | EA 7283 | 1 | 50% | 0.2% | 1 |
| 7 | GAST CANC BRANCH | 1 | 50% | 0.2% | 1 |
| 8 | GENENTECH EARLY DEV GRED | 1 | 50% | 0.2% | 1 |
| 9 | INTEGRATED DESIGN SCI | 1 | 50% | 0.2% | 1 |
| 10 | LIPADE EA 2517 | 1 | 50% | 0.2% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000218969 | SURROGATE ENDPOINT//PRENTICE CRITERION//PRENTICE CRITERIA |
| 2 | 0.0000173632 | LUNG CANCER SCREENING//PULMONARY NODULE//LOW DOSE COMPUTED TOMOGRAPHY |
| 3 | 0.0000086296 | SUNITINIB//METASTATIC RENAL CELL CARCINOMA//CARCINOMA RENAL CELL |
| 4 | 0.0000082652 | CT PERFUSION//PERFUSION COMPUTED TOMOGRAPHY//PAUL STRICKLAND SCANNER |
| 5 | 0.0000076321 | SUV//STANDARDIZED UPTAKE VALUE//LUNG NEOPLASMS EMISSION CT ECT |
| 6 | 0.0000070102 | EU LAW RISK REGULAT//EVOLUTIONARY FACTOR ANALYSIS//PUBLIC PRIVATE PEOPLE PARTNERSHIP 4P |
| 7 | 0.0000060438 | DCE MRI//PHARMACEUT MOL IMAGING//DYNAMIC CONTRAST ENHANCED MRI |
| 8 | 0.0000058069 | RENAL LENGTH//KIDNEY SIZE//KIDNEY DIMENSIONS |
| 9 | 0.0000055885 | F 18 FLT//F 18FLT//FLT |
| 10 | 0.0000055697 | INTRAVOXEL INCOHERENT MOTION//DIFFUSION WEIGHTED IMAGING//APPARENT DIFFUSION COEFFICIENT |